Becton, Dickinson and Company (NYSE:BDX) Shares Sold by Mackenzie Financial Corp

Mackenzie Financial Corp decreased its holdings in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 56.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 676,662 shares of the medical instruments supplier's stock after selling 873,411 shares during the quarter. Mackenzie Financial Corp owned approximately 0.24% of Becton, Dickinson and Company worth $153,514,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in BDX. Atomi Financial Group Inc. grew its holdings in Becton, Dickinson and Company by 25.3% in the 4th quarter. Atomi Financial Group Inc. now owns 1,056 shares of the medical instruments supplier's stock valued at $240,000 after buying an additional 213 shares during the period. Wesbanco Bank Inc. grew its holdings in shares of Becton, Dickinson and Company by 1.9% during the 4th quarter. Wesbanco Bank Inc. now owns 2,558 shares of the medical instruments supplier's stock worth $580,000 after purchasing an additional 48 shares during the period. Mutual Advisors LLC grew its holdings in shares of Becton, Dickinson and Company by 6.0% during the 4th quarter. Mutual Advisors LLC now owns 3,938 shares of the medical instruments supplier's stock worth $931,000 after purchasing an additional 222 shares during the period. Red Door Wealth Management LLC grew its holdings in shares of Becton, Dickinson and Company by 33.9% during the 4th quarter. Red Door Wealth Management LLC now owns 1,531 shares of the medical instruments supplier's stock worth $347,000 after purchasing an additional 388 shares during the period. Finally, Brighton Jones LLC grew its holdings in shares of Becton, Dickinson and Company by 98.2% during the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier's stock worth $401,000 after purchasing an additional 877 shares during the period. Hedge funds and other institutional investors own 86.97% of the company's stock.

Insider Activity at Becton, Dickinson and Company

In related news, EVP Michael David Garrison sold 479 shares of the company's stock in a transaction that occurred on Wednesday, April 9th. The stock was sold at an average price of $197.28, for a total transaction of $94,497.12. Following the sale, the executive vice president now directly owns 4,887 shares of the company's stock, valued at approximately $964,107.36. This represents a 8.93% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Richard Byrd sold 459 shares of the company's stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $230.00, for a total value of $105,570.00. Following the sale, the executive vice president now directly owns 6,952 shares in the company, valued at approximately $1,598,960. This represents a 6.19% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 2,878 shares of company stock valued at $636,393. Corporate insiders own 0.36% of the company's stock.

Becton, Dickinson and Company Stock Down 0.5%

Shares of BDX traded down $0.91 during trading on Friday, reaching $172.91. The company's stock had a trading volume of 691,929 shares, compared to its average volume of 1,928,535. The company has a fifty day moving average of $193.74 and a two-hundred day moving average of $217.14. Becton, Dickinson and Company has a twelve month low of $163.33 and a twelve month high of $251.99. The company has a market cap of $49.56 billion, a price-to-earnings ratio of 28.72, a P/E/G ratio of 1.63 and a beta of 0.31. The company has a quick ratio of 0.63, a current ratio of 1.13 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last announced its earnings results on Thursday, May 1st. The medical instruments supplier reported $3.35 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.28 by $0.07. The company had revenue of $5.27 billion for the quarter, compared to analyst estimates of $5.35 billion. Becton, Dickinson and Company had a return on equity of 15.74% and a net margin of 8.47%. Becton, Dickinson and Company's quarterly revenue was up 4.5% on a year-over-year basis. During the same period in the prior year, the company posted $3.17 EPS. On average, sell-side analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, June 30th. Investors of record on Monday, June 9th will be given a dividend of $1.04 per share. This represents a $4.16 annualized dividend and a dividend yield of 2.41%. The ex-dividend date of this dividend is Monday, June 9th. Becton, Dickinson and Company's dividend payout ratio is currently 79.39%.

Wall Street Analysts Forecast Growth

BDX has been the subject of a number of research reports. Citigroup cut Becton, Dickinson and Company from a "strong-buy" rating to a "hold" rating and decreased their target price for the stock from $217.00 to $185.00 in a report on Thursday, May 22nd. Barclays decreased their target price on Becton, Dickinson and Company from $279.00 to $261.00 and set an "overweight" rating for the company in a report on Monday, April 7th. Piper Sandler cut Becton, Dickinson and Company from an "overweight" rating to a "neutral" rating and decreased their price target for the stock from $260.00 to $185.00 in a report on Friday, May 2nd. Bank of America cut Becton, Dickinson and Company from a "buy" rating to a "neutral" rating and set a $190.00 price target for the company. in a report on Thursday, May 1st. Finally, William Blair cut Becton, Dickinson and Company from an "outperform" rating to a "market perform" rating in a report on Thursday, May 1st. Eight analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $221.44.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.